SAN DIEGO--(BUSINESS WIRE)--May 15, 2006--Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, has initiated a Phase I clinical trial of NPI-0052, a novel, small molecule proteasome inhibitor, to treat patients with solid tumors and lymphomas. The single-agent study is designed to evaluate the safety and tolerability of the anti-cancer compound.
